RU2013146213A - Новая комбинация, содержащая n-ацетил-l-цистеин, и ее применение - Google Patents

Новая комбинация, содержащая n-ацетил-l-цистеин, и ее применение Download PDF

Info

Publication number
RU2013146213A
RU2013146213A RU2013146213/15A RU2013146213A RU2013146213A RU 2013146213 A RU2013146213 A RU 2013146213A RU 2013146213/15 A RU2013146213/15 A RU 2013146213/15A RU 2013146213 A RU2013146213 A RU 2013146213A RU 2013146213 A RU2013146213 A RU 2013146213A
Authority
RU
Russia
Prior art keywords
medical product
product according
medical
intended
cysteine
Prior art date
Application number
RU2013146213/15A
Other languages
English (en)
Other versions
RU2605287C2 (ru
Inventor
Тицьяна ПАРАЗАССИ
Грациелла КОСТА
Эва КРАСНОВСКА
Эуджениа ПИТТАЛУГА
Original Assignee
Иасомай АБ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иасомай АБ filed Critical Иасомай АБ
Publication of RU2013146213A publication Critical patent/RU2013146213A/ru
Application granted granted Critical
Publication of RU2605287C2 publication Critical patent/RU2605287C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. Медицинский продукт, содержащий по отдельности или вместе:(1) N-ацетил-L-цистеин в дозе 5-45 мг/кг/сутки;(2) селен в форме селенометионина в дозе 0,4-1,2 мкг/кг/сутки и(3) мелатонин в дозе 0,02-0,08 мг/кг/суткии/или их физиологически приемлемые соли.2. Медицинский продукт по п.1 для одновременного, последовательного или раздельного комбинационного введения млекопитающему.3. Медицинский продукт по п.2, в котором компоненты (1), (2) и (3) предназначены для перорального введения.4. Медицинский продукт по п.1, представляющий собой фармацевтическую композицию, содержащую компоненты (1) N-ацетил-цистеин, (2) селенометионин и (3) мелатонин.5. Медицинский продукт по п.1, в котором компоненты (1) N-ацетил-цистеин, (2) селенометионин и (3) мелатонин предназначены для нанесения на кожу.6. Медицинский продукт по п.5, в котором компонент (1) предназначен для введения в концентрации 3-10% мас., компонент (2) предназначен для введения в концентрации 0,3-1% мас. и компонент (3) предназначен для введения в концентрации 0,01-0,2% мас.7. Медицинский продукт по любому из пп.1-6 для лечения доброкачественных или злокачественных неоплазий.8. Медицинский продукт по любому из пп.1-6 для лечения дерматологических заболеваний.9. Медицинский продукт по любому из пп.1-6 для косметического лечения кожи.10. Медицинский продукт по п.1 для применения в качестве антибактериального агента с медицинским устройством, адаптированным для применения в контакте с жидкостями организма.11. Медицинский продукт по п.10, где компоненты (1) N-ацетил-L-цистеин, (2) селенометионин и (3) мелатонин содержатся в гидрогелевом покрытии для медицинского устройства.12. Медицинский продукт по п.10 или 11, дополнительно содержащий �

Claims (19)

1. Медицинский продукт, содержащий по отдельности или вместе:
(1) N-ацетил-L-цистеин в дозе 5-45 мг/кг/сутки;
(2) селен в форме селенометионина в дозе 0,4-1,2 мкг/кг/сутки и
(3) мелатонин в дозе 0,02-0,08 мг/кг/сутки
и/или их физиологически приемлемые соли.
2. Медицинский продукт по п.1 для одновременного, последовательного или раздельного комбинационного введения млекопитающему.
3. Медицинский продукт по п.2, в котором компоненты (1), (2) и (3) предназначены для перорального введения.
4. Медицинский продукт по п.1, представляющий собой фармацевтическую композицию, содержащую компоненты (1) N-ацетил-цистеин, (2) селенометионин и (3) мелатонин.
5. Медицинский продукт по п.1, в котором компоненты (1) N-ацетил-цистеин, (2) селенометионин и (3) мелатонин предназначены для нанесения на кожу.
6. Медицинский продукт по п.5, в котором компонент (1) предназначен для введения в концентрации 3-10% мас., компонент (2) предназначен для введения в концентрации 0,3-1% мас. и компонент (3) предназначен для введения в концентрации 0,01-0,2% мас.
7. Медицинский продукт по любому из пп.1-6 для лечения доброкачественных или злокачественных неоплазий.
8. Медицинский продукт по любому из пп.1-6 для лечения дерматологических заболеваний.
9. Медицинский продукт по любому из пп.1-6 для косметического лечения кожи.
10. Медицинский продукт по п.1 для применения в качестве антибактериального агента с медицинским устройством, адаптированным для применения в контакте с жидкостями организма.
11. Медицинский продукт по п.10, где компоненты (1) N-ацетил-L-цистеин, (2) селенометионин и (3) мелатонин содержатся в гидрогелевом покрытии для медицинского устройства.
12. Медицинский продукт по п.10 или 11, дополнительно содержащий дополнительные активные соединения, такие как бактерицидные лекарственные средства, растворы благородных металлов и/или дексаметазон.
13. Антибактериальный агент, содержащий медицинский продукт по п.1.
14. Антибактериальный агент по п.13 для применения в гидрогелевом покрытии для медицинского устройства.
15. Антибактериальный агент по п.13 для интеграции с пластмассами медицинского устройства.
16. Медицинское устройство, содержащее медицинский продукт по п.1 и, возможно, дополнительное активное соединение, такое как бактерицидные лекарственные средства, растворы благородных металлов и/или дексаметазон.
17. Применение медицинского продукта по любому из пп.1-6 для лечения доброкачественной и злокачественной неоплазии, включая раковые заболевания различного вида, аутоиммунных заболеваний, нейродегенеративных заболеваний, эндокринологических заболеваний, диабета 2 типа, всех видов фиброза, амилоидоза, эндометриоза, синдрома поликистозных яичников, дисменореи, дерматологических заболеваний, включая витилиго, алопецию или псориаз, или бактериальных инфекций.
18. Применение медицинского продукта по любому из пп.1-6 для косметического лечения кожи.
19. Применение медицинского продукта по п.1 в качестве антибактериального агента с медицинским устройством, адаптированным для применения в контакте с жидкостями организма.
RU2013146213/15A 2011-04-01 2012-03-13 Новая комбинация, содержащая n-ацетил-l-цистеин, и ее применение RU2605287C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
SE1100238-3 2011-04-01
SE1100238 2011-04-01
US201161471162P 2011-04-03 2011-04-03
US61/471,162 2011-04-03
US201161508262P 2011-07-15 2011-07-15
SE1150696 2011-07-15
US61/508,262 2011-07-15
SE1150696-1 2011-07-15
PCT/EP2012/054360 WO2012130609A1 (en) 2011-04-01 2012-03-13 New combination comprising n-acetyl-l-cysteine and its use

Publications (2)

Publication Number Publication Date
RU2013146213A true RU2013146213A (ru) 2015-05-10
RU2605287C2 RU2605287C2 (ru) 2016-12-20

Family

ID=46929502

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013146213/15A RU2605287C2 (ru) 2011-04-01 2012-03-13 Новая комбинация, содержащая n-ацетил-l-цистеин, и ее применение

Country Status (7)

Country Link
US (4) US9795582B2 (ru)
EP (1) EP2694045B1 (ru)
JP (2) JP5895303B2 (ru)
CN (1) CN103608006B (ru)
AU (1) AU2012237327B2 (ru)
RU (1) RU2605287C2 (ru)
WO (1) WO2012130609A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103608006B (zh) * 2011-04-01 2017-07-07 伊亚索梅股份公司 包含n‑乙酰基‑l‑半胱氨酸的组合及其用途
CN104768614B (zh) 2012-11-09 2019-05-03 伊亚索梅股份公司 N-乙酰基-l-半胱氨酸在制备治疗体外受精药物中的用途
WO2015137983A1 (en) * 2014-03-14 2015-09-17 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
CA3060606A1 (en) * 2017-04-22 2018-10-25 Caidong Qin Method for inhibiting glycolysis in cells and use thereof
CN112307307B (zh) * 2019-07-24 2024-01-19 马上消费金融股份有限公司 一种保险产品推荐方法及装置
WO2023105482A1 (en) * 2021-12-10 2023-06-15 Institute For Stem Cell Science And Regenerative Medicine (Instem) Citric acid cycle and lactate transport inhibitors for prevention and/or treatment of skin disorders
WO2024052553A1 (en) * 2022-09-08 2024-03-14 Iasomai Ab Combination comprising n-acetyl-l-cysteine, selenomethionine and melatonine for treatment of anxiety disorder

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746674A (en) * 1985-08-27 1988-05-24 Cellena (Cell Engineering) Ag Melatonin compositions and uses thereof
JPH03145419A (ja) * 1989-10-31 1991-06-20 Shiseido Co Ltd 紫外線老化の防御薬剤
DE69329198T2 (de) * 1992-05-20 2001-05-17 Karen E. Burke Erneuerung von durch externe faktoren gealterter haut mittels transdermaler anwendung von selenoaminosäuren
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
FR2751536B1 (fr) * 1996-07-25 1998-11-06 Oreal Nouveaux derives de le melatonine anti-radicaux libres et compositions les comprenant
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
JP2001511153A (ja) * 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン 血管変性性疾患の予防および処置のための組成物および方法
JPH11286442A (ja) * 1998-04-01 1999-10-19 Ajinomoto Co Inc 炎症因子活性化抑制剤
CA2230389A1 (en) * 1998-04-28 1999-10-28 Murray N. Waldman Formulations containing melatonin to be topically applied for the purpose of protecting the skin from oxidative damage
US6207190B1 (en) 1998-08-13 2001-03-27 Chronorx, Llc Dosage forms for the treatment of the chronic glaucomas
US20030229141A1 (en) * 1999-01-08 2003-12-11 Yu Ruey J. N-acetyl cysteine and its topical use
IT1312377B1 (it) 1999-03-05 2002-04-15 Uni Ci S R L Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche
JP2001151153A (ja) 1999-11-25 2001-06-05 Neoex Lab Inc 中空構造物の中空部遮断具
SE518784C2 (sv) 2000-12-27 2002-11-19 Nactilus Ab "N-Acetyl-L-cystein med kompositioner för behandling av neoplasier"
US20040045566A1 (en) 2001-03-01 2004-03-11 Pera Ivo E. Tobacco smoke filter and relative composition made of antioxidant and mineral substances
DE10110418A1 (de) * 2001-03-05 2002-09-12 Asat Ag Applied Science & Tech Melatonin-Vitamin-A-Präparate
WO2003077900A1 (en) 2002-03-14 2003-09-25 Prevention, L.L.C. A unifying mechanism and methods to prevent cancer and neurodegenerative diseases
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
DE10226990A1 (de) * 2002-06-18 2004-03-18 Sanguibiotech Ag Topisch applizierbare Mikro-Emulsionen mit binärer Phasen- und Wirkstoffdifferenzierbarkeit, deren Herstellung und deren Verwendung, insbesondere zur Versorgung der Haut mit bioverfügbarem Sauerstoff
ITMI20021881A1 (it) * 2002-09-04 2004-03-05 Zambon Spa Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
EP1663339B1 (en) * 2003-08-14 2013-07-31 Blue Medical Devices B.V. Endoluminal prosthesis comprising a therapeutic agent
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
US20070231312A1 (en) 2006-04-04 2007-10-04 Muench Michael V Nutritional supplement for pregnant females
DE102007032686A1 (de) * 2007-07-13 2009-01-15 Biotronik Vi Patent Ag Stent mit einer Beschichtung
AU2009270849B2 (en) * 2008-07-17 2013-11-21 Micell Technologies, Inc. Drug delivery medical device
US20110027771A1 (en) 2009-07-31 2011-02-03 Artemis Health, Inc. Methods and compositions for cell stabilization
PL2305238T3 (pl) * 2009-09-25 2012-07-31 Iasomai Ab N-acetylo-L-cysteina do leczenia endometriozy
SG10201510085SA (en) * 2010-12-08 2016-01-28 Life Technologies Corp Control systems and methods for biological applications
CN103608006B (zh) * 2011-04-01 2017-07-07 伊亚索梅股份公司 包含n‑乙酰基‑l‑半胱氨酸的组合及其用途
CN104768614B (zh) * 2012-11-09 2019-05-03 伊亚索梅股份公司 N-乙酰基-l-半胱氨酸在制备治疗体外受精药物中的用途

Also Published As

Publication number Publication date
AU2012237327A1 (en) 2013-10-17
EP2694045A1 (en) 2014-02-12
US20180036276A1 (en) 2018-02-08
US20140030307A1 (en) 2014-01-30
US20190298680A1 (en) 2019-10-03
EP2694045B1 (en) 2019-10-30
JP2014509619A (ja) 2014-04-21
CN103608006B (zh) 2017-07-07
US10300038B2 (en) 2019-05-28
US9795582B2 (en) 2017-10-24
RU2605287C2 (ru) 2016-12-20
AU2012237327B2 (en) 2016-10-20
WO2012130609A1 (en) 2012-10-04
CN103608006A (zh) 2014-02-26
JP5895303B2 (ja) 2016-03-30
US20220110907A1 (en) 2022-04-14
JP2016065074A (ja) 2016-04-28
US11207287B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
RU2013146213A (ru) Новая комбинация, содержащая n-ацетил-l-цистеин, и ее применение
TN2013000293A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
MX369385B (es) Productos para cicatrizar heridas tisulares.
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
EA201390626A1 (ru) Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций
MX2014008021A (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
MX356343B (es) Compuestos que inhiben la exocitosis neuronal (ii).
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
RU2007101538A (ru) Применение фармацевтической композиции, содержащей кальцитриол и пропионат клобетазола, для лечения псориаза
EP2967076A2 (en) Compositions, methods and devices for promoting wound healing and reducing infection
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
AR075625A1 (es) Tratamiento de trastornos relacionados con la discinesia
RU2012149863A (ru) Полисахарид семени тамаринда для применения в лечении микробных инфекций
PT2459153E (pt) Composição farmacêutica ou cosmética ou dietética tendo o efeito de favorecer a pigmentação capilar
MX2011011058A (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
FI3071563T3 (fi) Syövän vastaisia aineita ja niiden valmistus
BR112015024871A2 (pt) composto, diastereoisômero ou epímero, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
AU2010275640A8 (en) Benzoquinolizinium salt derivatives as anticancer agents
RU2012149868A (ru) Полисахарид семян для применения в лечении воспалительных заболеваний